- About Us
- Nano-Social Network
- Nano Consulting
- My Account
June 22nd, 2006
Starpharma: A Buying Opportunity?
Jack Uldrich: Yesterday, shares of Starpharma’s ADR (Advance Deposit Receipts) plummetted 25 percent on no discernible news. I was surprised and disappointed by the drop — especially because I had just bought more shares the other day when the stock (Nasdaq: SPHRY) was trading at $3.50 and I didn’t think it could go any lower.
|Related News Press|
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016
Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016